Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
medical symbols : Oncs save search
Delisting of Securities of Puhui Wealth Investment Management Co., Ltd.; National Energy Services Reunited Corp.; Bed Bath & Beyond Inc.; IMV Inc.; Celyad Oncology SA; Aptinyx Inc.; Athenex, Inc.; Greencity Acquisition Corporation; QualTek Services Inc.; Bellicum Pharmaceuticals, Inc.; Wejo Group Limited; Cyxtera Technologies, Inc.; HTG Molecular Diagnostics, Inc.; Unico American Corporation; PolarityTE, Inc.; Oncorus, Inc.; and OncoSec Medical Incorporated from The Nasdaq Stock Market
Published: 2023-07-06 (Crawled : 20:00) - globenewswire.com
ONCSQ | $0.0001 43900.0% 820
|
Manufacturing
|
| O: -15.79%
H: 12.5%
C: -6.25%
CYXTQ | $0.0007 -57.14% 1.8K
|
|
| O: -4.89%
H: 17.73%
C: -5.28%
QTEKQ | $0.012 125.0% 640K
|
Construction
|
| O: -17.88%
H: 11.07%
C: -0.37%
ATNXQ | $0.0152 -85.53% 3.6K
|
Manufacturing
|
| O: 54.31%
H: 0.0%
C: -29.37%
IMVIQ | $0.0001 36400.0% 6K
|
Manufacturing
|
| O: -18.75%
H: 192.31%
C: 32.62%
ONCR | $0.126 -75.95% 140K
|
Health Technology
|
| O: -2.05%
H: 29.3%
C: 0.0%
NESR | $9.0 -36.31% 150K
|
Industrial Services
|
| O: 0.0%
H: 0.0%
C: 0.0%
NDAQ | $61.22 1.44% 1.42% 2.1M
|
Finance
|
| O: -0.22%
H: 0.8%
C: 0.18%
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: -14.11%
H: 7.11%
C: 6.2%
management nasdaq energy services beyond group acquisition medical molecular market
OncoSec is encouraged after FDA meeting to discuss proposed neoadjuvant melanoma clinical program
Published: 2023-05-16 (Crawled : 15:20) - biospace.com/
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: 3.9%
H: 54.12%
C: -35.35%
fda melanoma meeting program
OncoSec Receives $3.49 Million to Strengthen its Balance Sheet After Selling its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Authority NOL Program
Published: 2023-04-27 (Crawled : 12:00) - biospace.com/
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: -3.07%
H: 6.24%
C: 3.09%
program benefits
OncoSec Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Published: 2023-04-10 (Crawled : 16:00) - prnewswire.com
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: 53.57%
H: 24.42%
C: -26.16%
nasdaq direct offering
OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment
Published: 2023-04-03 (Crawled : 11:00) - prnewswire.com
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: -47.35%
H: 0.0%
C: 0.0%
ynote-695 keytruda melanoma treatment trial
OncoSec presents encouraging early data with TAVO™-EP combined with nivolumab (Opdivo®) in neoadjuvant melanoma
Published: 2022-11-15 (Crawled : 22:00) - prnewswire.com
ONCS | $0.2772 25.59% 52M
|
Health Services
| Email alert
Add to watchlist
opdivo melanoma nivolumab
OncoSec Announces Positive Clinical Data of the KEYNOTE-695 Trial Assessing TAVO-EP in Combination with Pembrolizumab (Keytruda®) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment
Published: 2022-11-11 (Crawled : 14:00) - biospace.com/
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: 3.85%
H: 0.0%
C: 0.0%
ynote-695 keytruda treatment melanoma trial positive
OncoSec Announces Pipeline Prioritization and Workforce Reduction
Published: 2022-10-04 (Crawled : 22:00) - prnewswire.com
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: 9.39%
H: 0.0%
C: -9.95%
Novel pre-clinical results regarding OncoSec's intratumoral electroporation platform were highlighted as Editor's Pick in Molecular Cancer Research
Published: 2022-06-24 (Crawled : 12:20) - prnewswire.com
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: -4.28%
H: 6.24%
C: -7.44%
research pre-clinical results molecular cancer platform preclinical
OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer
Published: 2022-04-29 (Crawled : 12:20) - prnewswire.com
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: 5.04%
H: 7.01%
C: 2.4%
Global Merkel Cell Carcinoma Disease Treatment Market (2021 to 2026) - Featuring Merck, Pfizer and Amgen Among Others
Published: 2022-03-01 (Crawled : 21:00) - prnewswire.com
MCK | $527.32 0.47% 0.0% 890K
|
Distribution Services
|
| O: 0.61%
H: 1.62%
C: 0.15%
BMY | $49.14 0.43% 0.0% 7.9M
|
Health Technology
|
| O: 0.19%
H: 0.71%
C: 0.13%
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: -0.84%
H: 2.11%
C: 1.05%
AMGN | News | $271.98 1.13% 1.12% 2.1M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: 0.0%
treatment disease cel cell carcinoma
OncoSec Announces Appointment of George Chi as Chief Financial Officer
Published: 2022-02-22 (Crawled : 00:00) - prnewswire.com
UL | $48.06 1.59% 0.0% 3.1M
|
Consumer Non-Durables
|
| O: 1.73%
H: 0.1%
C: -1.23%
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: 0.01%
H: 7.03%
C: -1.76%
CASI | $2.38 5.78% 5.46% 12K
|
Health Technology
|
| O: 0.7%
H: 3.42%
C: -2.47%
ces
OncoSec Announces Changes to its Board of Directors
Published: 2021-12-17 (Crawled : 14:30) - biospace.com/
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: -8.33%
H: 6.36%
C: 2.73%
OncoSec Provides Business Update
Published: 2021-10-20 (Crawled : 23:00) - biospace.com/
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: -1.58%
H: 3.74%
C: 1.34%
Intratumoral Cancer Therapies Market Size to Witness Substantial Boost at a CAGR of 43% in the 7MM During the Study Period 2018-30, Foresees DelveInsight
Published: 2021-09-27 (Crawled : 18:00) - prnewswire.com
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: -1.77%
H: 8.11%
C: 4.95%
cancer
Seelos Therapeutics Announces Appointment of Margaret Dalesandro to the Board of Directors
Published: 2021-09-02 (Crawled : 12:00) - prnewswire.com
GSK | News | $40.59 2.11% -0.36% 3.8M
|
Health Technology
|
| O: 0.07%
H: 0.83%
C: 0.7%
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: 0.0%
H: 0.9%
C: 0.84%
SEEL | $0.329 -1.64% -1.67% 200K
|
Health Technology
|
| O: 1.78%
H: 1.66%
C: -3.11%
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: -0.85%
H: 2.16%
C: 0.0%
Xilio Therapeutics Appoints Sara Bonstein to Its Board of Directors
Published: 2021-08-17 (Crawled : 12:00) - biospace.com/
JNJ | News | $149.12 0.82% 0.0% 9.3M
|
Health Technology
|
| O: -0.3%
H: 1.24%
C: 1.22%
SCPH | $4.57 0.22% 0.22% 110K
|
Health Technology
|
| O: -1.69%
H: 2.87%
C: 0.0%
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: -4.11%
H: 3.81%
C: 2.38%
INSM | $24.11 -0.86% -0.87% 3.3M
|
Health Technology
|
| O: -1.44%
H: 3.5%
C: 3.37%
ADXS | $0.572 12.48% 2.5K
|
Health Technology
|
| O: 2.94%
H: 0.0%
C: -4.29%
therapeutics
OncoSec to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference
Published: 2021-07-26 (Crawled : 13:15) - biospace.com/
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: -3.59%
H: 6.51%
C: 3.26%
biotech technology iot conference
OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma
Published: 2021-07-06 (Crawled : 20:00) - prnewswire.com
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: 20.43%
H: 26.49%
C: 1.19%
collaboration phase 3 keytruda
OncoSec Appoints Brian Leuthner as Interim Chief Executive Officer
Published: 2021-06-24 (Crawled : 00:00) - biospace.com/
ONCS | $0.2772 25.59% 52M
|
Health Services
|
| O: 2.36%
H: 0.86%
C: -1.44%
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.